S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
All the trading advice you’ve ever received boils down to this (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
All the trading advice you’ve ever received boils down to this (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
All the trading advice you’ve ever received boils down to this (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
All the trading advice you’ve ever received boils down to this (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Lacking counselors, US schools turn to the booming business of online therapy
All the trading advice you’ve ever received boils down to this (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars

C4 Therapeutics (CCCC) Earnings Date, Estimates & Call Transcripts

$1.60
-0.03 (-1.84%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.47
▼
$1.60
50-Day Range
$1.32
▼
$1.99
52-Week Range
$1.23
▼
$9.41
Volume
304,676 shs
Average Volume
300,527 shs
Market Capitalization
$78.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.33
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Feb. 22Estimated
Actual EPS
(Nov. 1)
-$0.55 Beat By $0.10
Consensus EPS
(Nov. 1)
-$0.65
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

CCCC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CCCC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

C4 Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.75)($0.71)($0.73)
Q2 20231($0.81)($0.81)($0.81)
Q3 20232($0.87)($0.71)($0.79)
Q4 20233($0.79)($0.58)($0.69)
FY 20238($3.22)($2.81)($3.02)

CCCC Earnings Date and Information

C4 Therapeutics last released its earnings results on November 1st, 2023. The reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.10. The company had revenue of $11.07 million for the quarter, compared to the consensus estimate of $6.94 million. C4 Therapeutics has generated ($2.75) earnings per share over the last year (($2.75) diluted earnings per share). Earnings for C4 Therapeutics are expected to decrease in the coming year, from ($2.53) to ($2.59) per share. C4 Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 22nd, 2024 based off prior year's report dates.

C4 Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/22/2024
Estimated)		------- 
11/1/2023Q3 2023($0.65)($0.55)+$0.10($0.55)$6.94 million$11.07 million
8/8/2023Q2 2023($0.74)($0.73)+$0.01($0.73)$8.65 million$2.66 million
5/4/2023Q1 2023($0.78)($0.71)+$0.07($0.71)$6.71 million$3.76 million
2/23/2023Q4 2022($0.72)($0.76)($0.04)($0.76)$8.56 million$2.85 million
11/3/2022Q3 2022($0.65)($0.65)-($0.65)$9.72 million$6.75 million
8/4/2022Q2 2022($0.68)($0.56)+$0.12($0.56)$7.79 million$13.83 million
5/5/2022Q1 2022($0.61)($0.65)($0.04)($0.65)$7.67 million$7.65 million
2/24/2022Q4 2021($0.59)($0.31)+$0.28($0.31)$7.16 million$20.08 million    
11/10/2021Q3 2021($0.57)($0.51)+$0.06($0.51)$7.28 million$8.50 million
8/10/2021Q2 2021($0.59)($0.51)+$0.08($0.51)$7.45 million$9.78 million
5/13/2021Q1 2021($0.63)($0.49)+$0.14($0.49)-$7.43 million












C4 Therapeutics Earnings - Frequently Asked Questions

When is C4 Therapeutics's earnings date?

C4 Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 22nd, 2024 based off last year's report dates. Learn more on CCCC's earnings history.

Did C4 Therapeutics beat their earnings estimates last quarter?

In the previous quarter, C4 Therapeutics (NASDAQ:CCCC) reported ($0.55) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.65) by $0.10. Learn more on analysts' earnings estimate vs. CCCC's actual earnings.

How much revenue does C4 Therapeutics generate each year?

C4 Therapeutics (NASDAQ:CCCC) has a recorded annual revenue of $31.10 million.

How much profit does C4 Therapeutics generate each year?

C4 Therapeutics (NASDAQ:CCCC) has a recorded net income of -$128.18 million. CCCC has generated -$2.75 earnings per share over the last four quarters.

What is C4 Therapeutics's EPS forecast for next year?

C4 Therapeutics's earnings are expected to decrease from ($2.53) per share to ($2.59) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:CCCC) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -